"For leading-edge cancer treatments, contact Regional Cancer Care Associates in Manchester, CT."

During the past decade, Regional Cancer Care Associates conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Regional Cancer Care Associates" are "Biliary Tract Neoplasms" (1 trials), "Carcinoma, Non-Small-Cell Lung" (1 trials), "HER2 Mutations Breast Neoplasms" (1 trials), "Leukemia, Myeloid, Acute" (1 trials) and "Myelodysplastic Syndromes" (1 trials). Many other conditions were trialed in "Regional Cancer Care Associates" in a lesser frequency.

Most popular intervention types in "Regional Cancer Care Associates" are "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "fulvestrant" (1 trials), "trastuzumab" (1 trials) and "tucatinib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Regional Cancer Care Associates" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Regional Cancer Care Associates". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Regional Cancer Care Associates, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Regional Cancer Care Associates, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".